New drug shows promise for rare, deadly heart condition
NCT ID NCT04622046
Summary
This study tested an experimental drug called ALXN2060 in Japanese patients with a serious heart condition caused by abnormal protein buildup. The main goals were to see if the drug could help patients walk farther and reduce their need for heart-related hospital visits. Twenty-five participants took the oral medication for up to 30 months while continuing their standard heart failure treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bunkyō City, 113-8431, Japan
-
Research Site
Fukuoka, 812-8582, Japan
-
Research Site
Kumamoto, 860-8556, Japan
-
Research Site
Kurume-shi, 830-0011, Japan
-
Research Site
Matsumoto-shi, 390-8621, Japan
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Nankoku-shi, 783-8505, Japan
-
Research Site
Sagamihara-shi, 252-0375, Japan
-
Research Site
Sapporo, 060-8543, Japan
-
Research Site
Shinjuku-ku, 160-8582, Japan
-
Research Site
Suita-shi, 564-8565, Japan
Conditions
Explore the condition pages connected to this study.